Related Experiment Videos
Hepatitis B virus e antigen and primary hepatocellular carcinoma
1Institute of Public Health, National Taiwan University College of Medicine, Taipei, Republic of China.
Anticancer Research
|November 1, 1991
Summary
Hepatitis B virus (HBV) infection markers, specifically hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), are significantly associated with primary hepatocellular carcinoma (PHC). HBeAg carrier status may amplify PHC risk in HBsAg-positive individuals.
Area of Science:
- Hepatology
- Virology
- Oncology
Background:
- Hepatitis B virus (HBV) infection is a major global health concern.
- HBV is a primary risk factor for the development of primary hepatocellular carcinoma (PHC).
- Understanding the specific roles of HBV markers in PHC pathogenesis is crucial.
Purpose of the Study:
- To investigate the association between various hepatitis B virus (HBV) infection markers and primary hepatocellular carcinoma (PHC).
- To evaluate the independent and interactive effects of HBV markers on PHC risk.
Main Methods:
- Serum samples from 243 PHC cases and 302 non-PHC controls were analyzed.
- Radioimmunoassays were used to detect HBV surface antigen (HBsAg), anti-HBs, anti-HBc, HBeAg, and anti-HBe.
- Statistical analysis, including odds ratios and stratification, was performed to assess marker associations.
Main Results:
- A high prevalence of HBV markers was observed in both PHC cases (97%) and controls (100%).
- Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) showed statistically significant associations with PHC (OR=10.0 and OR=3.2, respectively).
- HBeAg carrier status appeared to increase PHC risk in individuals positive for HBsAg.
Conclusions:
- HBsAg and HBeAg are significant risk factors for primary hepatocellular carcinoma.
- The presence of HBeAg may potentiate the risk of PHC in HBsAg carriers.
- These findings underscore the importance of HBV screening and management in PHC prevention strategies.